Skip to main content
Midas Edge

BiomX Inc

For the period ended Jun 30, 2024. Filed Aug 14, 2024.

View on SEC.gov

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Jun 30, 2024 · Filed Aug 14, 2024

HLSQ$0.07-37.4%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits
Contents

Condensed Consolidated Statements of Operations (unaudited)

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS

Three Months Ended June 30,Six Months Ended June 30,
2024202320242023
Research and development (“R&D”) expenses, net6,8973,81811,0028,382
General and administrative expenses2,8282,2555,5083,899
Operating loss9,7256,07316,51012,281
Other income(2,017)(90)(2,105)(181)
Interest expenses137458631,310
Income from change in fair value of Private Placement Warrants(11,868)-(3,858)-
Finance expense (income), net(329)(325)1,436(652)
Loss (income) before tax(4,476)6,40312,84612,758
Tax expenses581014
Net loss (income)(4,471)6,41112,85612,772
Basic loss (earnings) per share of Common Stock(0.01)0.120.190.31
Diluted loss per share of Common Stock0.070.120.190.31
Weighted average number of shares used in computing basic loss (earnings) per share of Common Stock69,809,42151,552,92366,059,51041,860,338
Weighted average number of shares used in computing diluted loss per share of Common Stock107,501,93251,552,92366,059,51041,860,338

CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN REDEEMABLE CONVERTIBLE

PREFERRED SHARES AND IN STOCKHOLDERS’ EQUITY (CAPITAL DEFICIENCY)

RedeemableConvertible Preferred Shares · RedeemableConvertible Preferred Shares · Common Stock · AdditionalPaid-in · Accumulated · TotalStockholders’ Equity(Capital
SharesAmountSharesAmountSharesAmountCapitalDeficitDeficiency)
Balance as of January 1, 2024----45,979,9303166,048(162,970)3,081
Issuance of Common Stock, Merger Warrants and Redeemable Convertible Preferred Shares upon the APT acquisition, net of issuance cost (***)40,47012,561--9,164,96813,227-3,228
Exercise of Pre-Funded Warrants into shares of Common Stock (**)--4,778,265*5-5
Issuance of Common Stock under At the Market Sales Agreement, net of $1 issuance costs (**)--75,179*19-19
Stock-based compensation expenses----909-909
Issuance of Redeemable Convertible Preferred Shares upon March 2024 PIPE, net of issuance costs (**)216,41719,859----541541
Net loss----(17,327)(17,327)
Balance as of March 31, 2024256,88732,420--59,998,3424170,749(180,297)(9,544)
Exercise of Pre-Funded Warrants into shares of Common Stock (**)--9,808,1051--1
Stock-based compensation expenses---77-77
Reclassification of Redeemable convertible preferred Shares to equity(256,887)(32,420)256,88732,420----32,420
Net income--4,4714,471
Balance as of June 30, 2024--256,88732,42069,806,4475170,826(175,826)27,425
(*)Less than $1.
(**)See Note 10A.
(***)See Note 1D.

CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN REDEEMABLE CONVERTIBLE

PREFERRED SHARES AND IN STOCKHOLDERS’ EQUITY (CAPITAL DEFICIENCY)

Common Stock · Additional Paid-in · Accumulated · Total Stockholders’
SharesAmountCapitalDeficitEquity
Balance as of January 1, 202329,976,5822157,838(136,801)21,039
Issuance of Common Stock and warrants under February 2023 PIPE, net of $176 issuance costs(**)3,199,491*1,293-1,293
Stock-based compensation expenses--175-175
Net loss---(6,361)(6,361)
Balance as of March 31, 202333,176,0732159,306(143,162)16,146
Issuance of Common Stock and warrants under February 2023 PIPE, net of $157 issuance costs**12,797,95715,8585,859
Stock-based compensation expenses--271271
Net loss(6,411)(6,411)
Balance as of June 30, 202345,974,0303165,435(149,573)15,865
(*)Less than $1.
(**)See Note 10A.
ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.